15 results about "Liver functions" patented technology

The present invention relates to a method for producing health-functional milk, comprising the step of selecting healthy dairy cows suitable for raw milk production by analyzing their health status after performing a comprehensive health examination including blood tests on dairy cows, and milking the selected dairy cows while feeding them a feed for constitutional improvement according to the lactation period after calving; wherein the comprehensive health examination includes protein metabolism, energy metabolism, liver function, and mineral metabolism. Accordingly, compared to milk produced by conventional methods, it can exhibit effects such as a fresh taste, reduced off-flavors and fishy tastes, and immune activity.

The application of mussel polysaccharide in preparation of a medicine for regulating the intestine-liver axis to treat alcoholic liver injury belongs to the technical field of natural products and biological medicine. The method takes mussel polysaccharide as an active ingredient, and divides experimental mice into a normal control group, an alcoholic liver injury model group, a positive control group and mussel polysaccharide low-, medium- and high-dose groups (60, 120 and 180 mg / kg / day), and continuously intervenes for 4 weeks. The results show that the mussel polysaccharide can significantly reduce liver function indexes such as ALT and AST, improve TC, TG, LDL-C, HDL-C related blood lipid disorders, protect the colon mucosal barrier, regulate the intestine-liver axis homeostasis, effectively reduce alcohol-induced liver fatty degeneration, inflammatory infiltration and oxidative stress injury, and the effect shows obvious dose dependence. The mussel polysaccharide is safe, non-toxic, economical in source, simple in intervention method and strong in repeatability, and provides a new way for the development of functional food and liver protection products for preventing and treating alcoholic liver injury.

The application discloses application of coenzyme Q10 and a composition containing coenzyme Q10 in preparation of a medicine for preventing and treating duck hepatitis A virus type 1, and relates to the technical field of veterinary antiviral medicines. The application finds through experiments that coenzyme Q10 and the composition containing coenzyme Q10 have a protective effect on duck hepatitis A virus type 1 infection. The composition contains coenzyme Q10 and egg yolk antibodies. The combination of coenzyme Q10 and egg yolk antibodies can relieve inflammatory reactions caused by duck hepatitis A virus type 1, reduce liver oxidative application, alleviate liver function damage caused by duck hepatitis A virus type 1, and reduce the viral load of duck hepatitis A virus type 1, so that the dual synergy of 'antiviral' and 'anti-inflammatory liver protection' is realized. The application first finds the application value of the combination of coenzyme Q10 and egg yolk antibodies in the prevention and treatment of DHAV-1 infection, and provides a new technical strategy for the prevention and treatment of duck viral hepatitis.

Provided are Christensenellaceae, and a composition and a pharmaceutical use thereof. The Christensenellaceae can be used for treating or preventing liver function damage and related diseases, digestive tract mucosa damage and related diseases, diabetes, obesity, and related diseases. The Christensenellaceae can also be used in combination with hypoglycemic and lipid-lowering drugs, and has a synergistic effect on liver function damage and related diseases, diabetes, and obesity and related diseases.

The application discloses a kind of Miao medicine composition for treating liver fibrosis and cirrhosis ascites and its preparation method and application, belong to traditional Chinese medicine and national medical technology field.The composition is made of specific weight ratio of chases yellow grass, pearl grass, white flower snake tongue grass, bupleurum, vinegar baked turtle shell, Miao medicine soft liver grass (dried whole grass of gold star fern), catpaw grass, rhizoma sparganii, zedoary, peach kernel, rehmannia, astragalus, atractylodes, angelica, salvia miltiorrhiza, calcined oyster, big belly skin, poria cocos, curcuma, prepared rehmannia, white peony root, chuanxiong.The application provides pill, granule, capsule and the like controllable preparation process, and the product quality is stable, and safety is high.Experiment and clinic confirm that the composition can significantly reverse liver fibrosis, quickly subsides cirrhosis ascites and reduces recurrence rate, simultaneously improves liver function, liver elasticity, serum albumin and blood coagulation function, is suitable for long-term treatment of liver fibrosis and cirrhosis ascites, and has good industrial application prospect.

The present application relates to the field of biological medicine and functional food, and discloses a kind of nutrition composition based on marine shrimp peptide for anti-obesity and improving metabolic syndrome;Including: Chinese tube whip shrimp peptide active component and pharmaceutically acceptable adjuvant, the Chinese tube whip shrimp meat protein is used as raw material, and the Chinese tube whip shrimp meat protein is prepared by alkaline protease enzymolysis, and the Chinese tube whip shrimp meat protein contains peptide segment with molecular weight less than 1 kDa, and APPPPP, HPPPP and MPLPP can be detected.The pharmaceutical composition can reduce the weight and fat tissue weight under the state of obesity, improve dyslipidemia, abnormal liver function and liver steatosis, reduce oxidative stress level, improve intestinal mucosal barrier damage and intestinal permeability increase, and regulate intestinal flora structure change.The active component in the present application is clear in origin, and the preparation process is clear, has the synergistic effect from lipid metabolism regulation, liver protection to intestinal barrier improvement, and can be used for preparing medicine for preventing or treating obesity and improving metabolic syndrome.

The present application relates to the application of mitochondrial transplantation preparation in the preparation of a drug for treating non-alcoholic fatty liver disease, wherein the mitochondrial transplantation preparation comprises active mitochondria isolated from healthy donor cells, and has normal membrane potential and mitochondrial respiratory function. In vivo experiments on a non-alcoholic fatty liver mouse model prove that tail vein injection of the mitochondrial transplantation preparation of the present application can effectively reduce the weight of the mouse, improve the fatty liver condition of the mouse, reduce the accumulation of fat in the liver tissue, and at the same time restore the abnormal liver function of the non-alcoholic fatty liver mouse.

The application discloses application of 1,5-dicaffeoylquinic acid in prevention and / or treatment of non-alcoholic fatty liver disease and weight loss and blood lipid reduction, and belongs to the technical field of biological medicine. The application first proposes application of 1,5-dicaffeoylquinic acid in preparation of a medicine for preventing and / or treating metabolic related fatty diseases. In-vivo and in-vitro experimental results show that after 1,5-dicaffeoylquinic acid is used in an in-vitro and in-vivo NAFLD model, the weight can be reduced, liver function and blood lipid abnormality, sugar metabolism abnormality and lipid accumulation can be relieved; the 1,5-dicaffeoylquinic acid can be used for preparing a medicine for preventing or treating NAFLD, obesity and blood lipid reduction, and the new use of the 1,5-dicaffeoylquinic acid in resisting NAFLD is confirmed, so that the 1,5-dicaffeoylquinic acid is expected to be developed into a new type of NAFLD resisting medicine, and has a wide market prospect.

The present application relates to the technical field of biological medicine, and particularly relates to a polypeptide for treating non-alcoholic fatty liver disease. The present application provides a novel octapeptide P3-1 (SEQ ID NO: 1) derived from macadamia nut, which can significantly improve liver lipid metabolism disorder, restore liver function, reduce inflammatory response and increase probiotic abundance in non-alcoholic fatty liver disease mice induced by high-fat diet. The polypeptide has small molecular weight, safe source and easy absorption, has good potential for pharmaceutical development, and provides a safe and effective new way for targeted intervention of non-alcoholic fatty liver disease.

This invention provides the application of leek or konjac exosome vesicles in the preparation of drugs for the prevention or treatment of obesity. Through examples, this invention demonstrates that leek exosome vesicles (Allium tuberosum exosome vesicles, AtExVs) and konjac exosome vesicles (Amorphophallus konjac exosome vesicles, AkExVs), administered rectally, can effectively inhibit the development of obesity in the early stages induced by a high-fat diet. Specifically, this is manifested in significantly slowing weight gain, reducing body fat percentage, decreasing the accumulation of abdominal white fat and epididymal fat, and improving liver function. Simultaneously, AtExVs and AkExVs intervention partially restored the decline in gut microbiota diversity caused by a high-fat diet, altering the overall structure of the microbiota, particularly significantly increasing the relative abundance of the beneficial bacteria family Lachnospiraceae.

This invention relates to a morel lectin, its preparation method, and its application, belonging to the field of biotechnology. The amino acid sequence of the morel lectin of this invention is shown in SEQ ID NO.1. The morel lectin is obtained by ultrafiltration, saturated ammonium sulfate precipitation, dialysis, microporous membrane filtration, Q Beads 6FF ion chromatography, dialysis, and freeze-drying of the supernatant after homogenizing morel mushrooms with water. The morel lectin is used to treat non-alcoholic fatty liver disease (NAFLD), inhibiting weight gain, reducing hepatomegaly, lowering blood lipid levels, improving obesity symptoms, reducing hepatic steatosis and liver function damage, and effectively treating NAFLD.

This invention discloses the application of Xinnaoning capsules in the preparation of drugs for treating non-alcoholic fatty liver disease (NAFLD), belonging to the field of pharmaceutical technology. Using a high-fat diet-induced NAFLD model in SD rats, this invention demonstrates that Xinnaoning capsules can significantly reduce liver and serum total cholesterol and triglyceride levels, lower alanine aminotransferase (ALT) and aspartate aminotransferase (AST) to protect liver function, downregulate inflammatory factors such as tumor necrosis factor-α, interleukin-6, and interleukin-1β, improve insulin resistance, and alleviate hepatic steatosis and inflammatory damage in a dose-dependent manner, with higher doses showing better effects. This invention provides a safe, multi-target traditional Chinese medicine treatment for NAFLD, expands the clinical indications of Xinnaoning capsules, and has significant academic value and clinical application prospects.

The present invention relates to a composition for preventing, ameliorating, or treating kidney and liver diseases, comprising a complex (NEPROBIN) of Ganoderma lucidum extract and Robinia pseudoacacia flower extract as an active ingredient. The complex provided from the present invention exhibits excellent effects in preventing kidney damage, maintaining kidney function, and regenerating kidney tissue by means of inhibition of NO production, reduction in cytokine (TNF-a) and Crp gene expression, increase in glutathione, reduction in ROS production, and increase in uremic toxin excretion, and exhibits excellent effects in preventing liver damage and improving liver function by means of inhibition of NO production, reduction in cytokine (IL6) and MCP1 and CXCL1 gene expression, increase in glutathione, suppression of expression of fibrosis markers (ACTA2, Vim, COL3A1) of hepatic stellate cells, restoration of GSH in liver tissue, increase in antioxidant enzyme activity, and suppression of expression of antiinflammatory- and antifibrotic-related genes and proteins, and thus, the complex is applicable as a pharmaceutical composition for preventing or treating kidney and / or liver diseases, and as a health functional food and food composition for preventing or ameliorating liver diseases.

This invention discloses the application of leonurin in the preparation of drugs for reducing serum total bilirubin levels, belonging to the field of traditional Chinese medicine technology. Through the construction of different types of hyperbilirubin animal models, this invention is the first to discover that leonurin can significantly reduce serum total bilirubin levels, and can be used to treat hyperbilirubinemia, alleviate bilirubin elevation caused by cholestasis, and treat acute abnormal bilirubin elevation. Simultaneously, leonurin does not cause abnormalities in liver function indicators such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) during the bilirubin-lowering process, demonstrating good safety. This invention also provides a pharmaceutical composition containing leonurin and its preparation method. This invention provides a new drug option for the treatment of hyperbilirubinemia.